India’s February 2026 drug quality alert flagged 198 failed batches, with blood pressure medicines most affected. Telmisartan accounted for 13 failures across eight manufacturers, all failing dissolution tests. Such silent failures undermine hypertension control. Other alerts revealed contaminated, spurious, or ineffective medicines, showing systemic lapses in pharmaceutical quality.